Epilepsy News and Research

Latest Epilepsy News and Research

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

14 Jun 2010

Astrocytes involved in regulation of signalling between neurons: Study

Astrocytes are the most common type of cell in the brain and play an important role in the function of neurons - nerve cells. New research from the University of Gothenburg, Sweden, shows that they are also directly involved in the regulation of signalling between neurons.

14 Jun 2010

Study: Children with idiopathic onset epilepsy have high remission rate

A study conducted by researchers in The Netherlands confirmed that children with idiopathic new-onset epilepsy have a significantly higher rate of remission than those with remote symptomatic epilepsy.

14 Jun 2010

HDMA honors Upsher-Smith with two DIANA Awards

Upsher-Smith announced today that they are the recipients of two Distribution Industry Awards for Notable Achievements in Healthcare given by the Healthcare Distribution Management Association. The Company was presented with two DIANAs in the 'Best Overall Manufacturer' Awards category. Within this category, Upsher-Smith was the winner for the second time since 2008 of the 'Best Branded Pharmaceutical Company with Sales to Healthcare Distributors of less than $300 Million.'

10 Jun 2010

Brain stimulation with ultrasound may enhance cognitive function

The ability to diagnose and treat brain dysfunction without surgery, may rely on a new method of noninvasive brain stimulation using pulsed ultrasound developed by a team of scientists led by William "Jamie" Tyler, a neuroscientist at Arizona State University. The approach, published in the journal Neuron on June 9, shows that pulsed ultrasound not only stimulates action potentials in intact motor cortex in mice but it also "elicits motor responses comparable to those only previously achieved with implanted electrodes and related techniques," says Yusuf Tufail, the lead author from ASU's School of Life Sciences.

10 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Aestus Therapeutics, Inc. announced that it has been awarded a $2 million Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). The grant, from the NIH's National Institute of Neurological Disorders and Stroke (NINDS), will fund clinical trials of Aestus's novel, first-in-class treatment for chronic neuropathic pain.

9 Jun 2010

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

At the Organization of Human Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10), Elekta unveiled its next generation magnetoencephalography system, Elekta Neuromag TRIUX. A platform that addresses key requirements critical for monitoring normal and abnormal brain activity, Elekta Neuromag TRIUX was designed to operate in virtually any clinical environment – an advance welcomed by the growing number of Elekta Neuromag clinical and research facilities worldwide.

From Elekta 7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Firms chase opportunities in online medicine

General Electric Co. chief executive Jeffrey Immelt urged Japan, at a conference in Tokyo Monday, to use health information technology to improve home-based health care as a hedge against the strains of an aging population, The Wall Street Journal reports. Japan's over-65 population is growing, and could top 30 percent by 2030.

2 Jun 2010

Epilepsy surgery ends seizures and prevents further deterioration in memory

Patients with drug-resistant epilepsy run the risk of gradual deterioration in their cognitive abilities. Surgical treatment generally puts an end to seizures but can have a negative effect on memory. However, there is no further deterioration in memory, and some patients may even recover some of their memory capacity, reveals a thesis from the University of Gothenburg.

31 May 2010

Neurological Institute at University Hospitals receives Neuroscience Center of Excellence designation

The Neurological Institute at University Hospitals has been designated as a Neuroscience Center of Excellence (COE), according to the Neuroscience Center of Excellence Survey sponsored by NeuStrategy, Inc., Chicago. It is the first neurological program in Ohio to receive the Stage 4 - Institute designation.

27 May 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty today in U.S. District Court in Boston to one count of misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its epilepsy drug Topamax for uses that were not approved by the FDA. The company was also sentenced at today's hearing.

24 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research at the Hilton Atlanta in Atlanta, Georgia.

20 May 2010

Children with new/recent onset epilepsy have slowed expansion of white matter volume

A newly published study reported that children with new/recent onset epilepsy have significantly slowed expansion of white matter volume compared to healthy children over a two year interval. The reduced white matter volume may affect brain connectivity and influence cognition. Results of this study conducted by researchers from the University of Wisconsin School of Medicine and Public Health are now available online and will appear in the July issue of Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

19 May 2010

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

Epilepsy News and Research

Latest Epilepsy News and Research

UCB announces availability of Vimpat oral solution formulation

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Astrocytes involved in regulation of signalling between neurons: Study

Study: Children with idiopathic onset epilepsy have high remission rate

HDMA honors Upsher-Smith with two DIANA Awards

Brain stimulation with ultrasound may enhance cognitive function

Mutations in ion channels cause rare inherited pain disorder: Research

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Firms chase opportunities in online medicine

Epilepsy surgery ends seizures and prevents further deterioration in memory

Neurological Institute at University Hospitals receives Neuroscience Center of Excellence designation

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

NeuroTherapeutics Pharma closes $43 million Series B financing round

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Children with new/recent onset epilepsy have slowed expansion of white matter volume

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Epilepsy News and Research

Latest Epilepsy News and Research

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in